Genetically predicted inhibition of PCSK9 was associated with lower risk of CAD but not T2D, and genetically predicted inhibition of HMGCR was associated with lower risk of CAD, but higher risk of T2D (Figure 2B). This evidence concerns the gene PCSK9 and coronary artery disorder.